TPI 287 Injection

DRUG2 trials

Sponsors

Cortice Biosciences, Inc.

Conditions

Hodgkin DiseaseHodgkin's DiseaseNeoplasmsNon-Hodgkin LymphomaNon-Hodgkin's Lymphoma

Phase 1

Study of TPI 287 in Patients With Advanced Malignancies

CompletedNCT00113724

Cortice Biosciences, Inc.Hodgkin Disease, Neoplasms, Non-Hodgkin Lymphoma

Start: 2005-05-31End: 2008-01-31Target: 48Updated: 2009-06-04

Study of TPI 287 Administered Every 21 Days in Patients With Advanced Malignancies

CompletedNCT00256191

Cortice Biosciences, Inc.Hodgkin's Disease, Neoplasms, Non-Hodgkin's Lymphoma

Start: 2005-11-30End: 2007-02-28Target: 45Updated: 2007-10-15